Alere Inc

Most Recent

  • uploads///ALR ABT ABT basics
    Miscellaneous

    What You Need to Know about the Abbott Labs Side of the Alere-Abbott Merger

    Abbott Laboratories is a leading pharmaceutical company that also makes diagnostic products, nutritional products, and vascular products.

    By Brent Nyitray, CFA, MBA
  • uploads///US Leveraged Loans Flows
    Company & Industry Overviews

    Leveraged Loan Funds: Ongoing Outflows in June

    Last week’s quantum of outflows was $223 million. This brings the total net outflows from leveraged loan funds to $4.3 billion year-to-date.

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    Waters Introduces Symphony, Its New Data Pipeline Software

    A top IHI performer on June 2, 2016, was Waters (WAT), which rose 0.9%. The company was in the news with the introduction of its new data pipeline software.

    By Peter Neil
  • uploads///ALR ABT acquisition
    Company & Industry Overviews

    A Brief Recap of the Abbott–Alere Deal Developments

    Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.

    By Sarah Collins
  • uploads///ALR ABT acquisition
    Company & Industry Overviews

    Abbott-Alere Deal Wins Conditional US Antitrust Approval

    The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories’ (ABT) acquisition of Alere (ALR).

    By Sarah Collins
  • uploads///ST JUDE
    Earnings Report

    What Were Abbott’s Key Growth Drivers for 2Q17?

    Abbott completed the acquisition of St. Jude Medical in January 2017. It contributed significantly to its 2Q17 sales.

    By Sarah Collins
  • uploads///Graph
    Miscellaneous

    Does Novartis See Much Potential for Its Surgical Business?

    In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.

    By Margaret Patrick
  • uploads///adverse events
    Company & Industry Overviews

    Alere’s Response to Abbott Laboratories’s Lawsuit to Terminate the Merger

    Alere (ALR) denied claims that any of the events that occurred during the last ten months would constitute any material change to the company’s value.

    By Sarah Collins
  • uploads///q performance
    Earnings Report

    Abbott’s Stock Prices Fell despite Strong 3Q16 Results

    On October 19, Abbott Laboratories (ABT) released its 3Q16 earnings. After the announcement, its share price fell ~2% from $41.2 on October 18, 2016.

    By Sarah Collins
  • uploads///medical optics
    Company & Industry Overviews

    The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics

    On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.

    By Sarah Collins
  • uploads///STJ ABT portfolio
    Miscellaneous

    Rationale for the St. Jude Medical-Abbott Merger Transaction

    Abbott Labs is buying St. Jude Medical for about $30 billion in cash, stock, and assumed debt to become a dominant player in the cardiovascular health space.

    By Brent Nyitray, CFA, MBA
  • uploads///ALR ABT ALR basics
    Miscellaneous

    The Alere-Abbott Labs Merger: Understanding the Alere Side

    Alere provides diagnostic solutions in the healthcare industry, primarily in infectious disease. Abbott Labs is buying Alere to boost its diagnostics line.

    By Brent Nyitray, CFA, MBA
  • uploads///cphd pm
    Earnings Report

    Cepheid’s Revenue and Income Fell in 3Q15

    After its 3Q15 earnings report, Cepheid fell by 0.86% to close at $32.25 per share as of October 20, 2015, with a 4.8% fall in revenue in 3Q15.

    By Gabriel Kane
  • uploads///Positions
    Fund Managers

    Steven Cohen’s Point72 Asset Management’s 3Q14 positions

    Point72 Asset Management’s portfolio decreased slightly to $13.2 billion in the third quarter—compared to $15.6 billion in the second quarter. The third quarter ended in September.

    By Diana Key
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.